Skip To Main Content
Huiying Han on Muck Rack

Huiying Han

As seen in: Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Huiying

Contact Huiying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors

|
By Mihai I. Truica, Michael Burns, Huiying Han, Sarki A. Abdulkadir
| cancerres.aacrjournals.org
Reviews Mihai I. Truica, Michael C. Burns, Huiying Han and Sarki A. Abdulkadir DOI: 10.1158/0008-5472.CAN-20-2959 Published January 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below. Abstract MYC is a highly validated oncogenic transcription factor and cancer target.
Open in Who Shared Issue with article?

Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors

|
By Mihai I. Truica, Michael Burns, Huiying Han, Sarki A. Abdulkadir
| cancerres.aacrjournals.org
Review Mihai I. Truica, Michael C. Burns, Huiying Han and Sarki A. Abdulkadir DOI: 10.1158/0008-5472.CAN-20-2959 Abstract MYC is a highly validated oncogenic transcription factor and cancer target. However, the disordered nature of this protein has made it a challenging target, with no clinical stage, direct small-molecule MYC inhibitors available.
Open in Who Shared Issue with article?

Turning up the heat on MYC: Progress in small molecule inhibitors

|
By Mihai I. Truica, Michael Burns, Huiying Han, Sarki A. Abdulkadir
| cancerres.aacrjournals.org
Review Mihai I Truica, Michael C. Burns, Huiying Han and Sarki A. Abdulkadir DOI: 10.1158/0008-5472.CAN-20-2959 Abstract MYC is a highly validated oncogenic transcription factor and cancer target. However, the disordered nature of this protein has made it a challenging target, with no clinical stage, direct small molecule MYC inhibitors available.
Open in Who Shared Issue with article?
See all 6 articles